Karsenty Clément, Vignaud Paul, Brusq Clara, Moceri Pamela, Lim Pascal, Gerbaud Edouard, Lairez Olivier, Lelarge Coline, Ovaert Caroline, Bouleti Claire, Werner Oscar, Bongard Vanina, Genet Thibaud, Bonnemains Laurent, Tron Christophe, Barre Elise, Boddaert Margaux, Mansourati Jacques, Benzouid Chérine, Roubille François, Khachab Hadi, Uhry Sabrina, Cohen Ariel, Lattuca Benoit, Di Filippo Sylvie, Delmas Clément
Department of Pediatric Cardiology, University Hospital, Toulouse, France.
Institut des Maladies Métaboliques et Cardiovasculaires, University of Toulouse, Toulouse, France.
ESC Heart Fail. 2025 Aug;12(4):2932-2945. doi: 10.1002/ehf2.15304. Epub 2025 May 22.
Acute myocarditis (AM) is a rare but severe disease affecting patients of all ages. Large multicentric studies comparing children and adults are currently lacking. We aimed to elucidate differences in presentation, management, and outcomes of AM across age groups.
We analysed a comprehensive French national cohort study, encompassing 53 paediatric and adult units from March 2020 to November 2021, collecting data on baseline characteristics, evolution, management and in-hospital complications. Myocarditis-related events (MRE) within 30 days included all-cause death, cardiogenic shock, cardiac arrest, ventricular arrhythmias or complete AV block.
We included 745 AM patients (328 children and 417 adults), mainly male (73.4%) with a median age of 10.9 years [Q1-Q3 (7.3-14.6)] for children and 28.7 years [22.6-41.2] for adults. Multisystem inflammatory syndrome (MIS) was more prevalent among children (69.8%), and infectious aetiologies dominated in adults (13.4 vs. 52.4%). Children exhibited more severe clinical presentation (15.9 vs. 7.2%, P < 0.001, with heart failure and 14.4 vs. 6.9%, P < 0.001, with cardiogenic shock), requiring higher use of inotropes (25.0 vs. 9.4%, P < 0.001), vasopressors (12.0 vs. 6.2%, P < 0.001), and ventilatory support (13.7% vs. 7.9%, P = 0.01). Cardiac treatments were used less frequently in children, and corticosteroids (68.3 vs, 14.3, P < 0.001) and immunomodulators (65.1 vs. 4.5%, P < 0.001) were more common. MRE occurrence was substantial but not significantly different between children and adults (18.1 vs. 13.4%, P = 0.09). Extra-cardiac manifestations at admission were significant predictors of MRE [adjusted odds ratio 2.40 (1.43-4.38)], regardless of MIS status.
AM exhibits variations in presentation, aetiologies and management but has a comparable 30 day prognosis in children and adults. These findings underscore the importance of tailored management strategies in AM across different age groups.
急性心肌炎(AM)是一种罕见但严重的疾病,可影响各年龄段患者。目前缺乏比较儿童和成人的大型多中心研究。我们旨在阐明不同年龄组AM在临床表现、治疗及预后方面的差异。
我们分析了一项全面的法国全国队列研究,该研究涵盖了2020年3月至2021年11月期间的53个儿科和成人科室,收集了关于基线特征、病情演变、治疗及院内并发症的数据。30天内与心肌炎相关的事件(MRE)包括全因死亡、心源性休克、心脏骤停、室性心律失常或完全性房室传导阻滞。
我们纳入了745例AM患者(328例儿童和417例成人),主要为男性(73.4%),儿童的中位年龄为10.9岁[四分位间距(Q1-Q3)为7.3-14.6岁],成人为28.7岁[22.6-41.2岁]。多系统炎症综合征(MIS)在儿童中更为常见(69.8%),而感染性病因在成人中占主导(13.4%对52.4%)。儿童表现出更严重的临床表现(心力衰竭为15.9%对7.2%,P<0.001;心源性休克为14.4%对6.9%,P<0.001),需要更多地使用正性肌力药物(25.0%对9.4%,P<0.001)、血管升压药(12.0%对6.2%,P<0.001)和通气支持(1